Clinical and pathologic predictors of locoregional recurrence, distant metastasis, and overall survival in patients treated with chemoradiation and mesorectal excision for rectal cancer

American Journal of Clinical Oncology: Cancer Clinical Trials

Volumn 29, Issue 3, 2006, Pages 219-224

  Das, Prajnan ^a   Skibber, John M ^a   Rodriguez Bigas, Miguel A ^a   Feig, Barry W ^a   Chang, George J ^a   Hoff, Paulo M ^a   Eng, Cathy ^a   Wolff, Robert A ^a   JanJan, Nora A ^a   Delclos, Marc E ^a   Krishnan, Sunil ^a   Levy, Lawrence B ^a   Ellis, Lee M ^a   Crane, Christopher H ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

Cox model; Local recurrence; Metastasis; Predictive factors; Rectal cancer; Survival

Indexed keywords

CISPLATIN; FLUOROURACIL; FOLINIC ACID; LEVAMISOLE; TEGAFUR; URACIL DERIVATIVE; ANTINEOPLASTIC ANTIMETABOLITE;

ADULT; AGED; ARTICLE; CANCER LOCALIZATION; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; CELL INVASION; DISEASE FREE INTERVAL; FEMALE; FOLLOW UP; HISTOPATHOLOGY; HUMAN; MAJOR CLINICAL STUDY; MALE; METASTASIS; MULTIMODALITY CANCER THERAPY; OVERALL SURVIVAL; PREDICTION; PROPORTIONAL HAZARDS MODEL; RADIATION DOSE; RECTUM CANCER; TUMOR VOLUME; UNIVARIATE ANALYSIS; ADJUVANT CHEMOTHERAPY; AGE; MIDDLE AGED; PATHOLOGY; PROGNOSIS; RECTUM TUMOR; SEX DIFFERENCE; SURVIVAL; TUMOR RECURRENCE;

ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; ANTIMETABOLITES, ANTINEOPLASTIC; CHEMOTHERAPY, ADJUVANT; COMBINED MODALITY THERAPY; FEMALE; FLUOROURACIL; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PROGNOSIS; RECTAL NEOPLASMS; SEX FACTORS; SURVIVAL;

EID: 33744971129     PISSN: 02773732     EISSN: 1537453X     Source Type: Journal    
DOI: 10.1097/01.coc.0000214930.78200.4a     Document Type: Article

References (19)

1. Anonymous. Prolongation of the disease-free interval in surgically treated rectal carcinoma. Gastrointestinal Tumor Study Group. N Engl J Med. 1985;312:1465-1472.
2. Krook JE, Moertel CG, Gunderson LL, et al. Effective surgical adjuvant therapy for high-risk rectal carcinoma. N Engl J Med. 1991;324:709-715.
3. O'Connell M, Martenson JA, Wieand HS, et al. Improving adjuvant therapy for rectal cancer by combining protracted-infusion fluorouracil with radiation therapy after curative surgery. N Engl J Med. 1994;331:502-507.
4. Sauer R, Becker H, Hohenberger W, et al. Preoperative versus postoperative chemoradiotherapy for rectal cancer. N Engl J Med. 2004;351:1731-1740.
5. Gunderson LL, Sargent DJ, Tepper JE, et al. Impact of T and N stage and treatment on survival and relapse in adjuvant rectal cancer: a pooled analysis. J Clin Oncol. 2004;22:1785-1796.
6. Fleming I, Cooper J, Henson D, et al., eds. AJCC Cancer Staging Handbook, 5th ed. Philadelphia: Lippincott, 1997.
7. Kaplan E, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;53:457-481.
8. Sauer R, Roedel C, Martus P, et al. Prognostic factors after neoadjuvant radiochemotherapy for rectal cancer: update of the CAO/ARO/AIO-94 phase III study. J Clin Oncol. 2005;23:246s.
9. Roman S, Cenni JC, Roy P, et al. Value of rectal ultrasound in predicting staging and outcome in patients with rectal adenocarcinoma. Dis Colon Rectum. 2004;47:1323-1330.
10. Benson AB 3rd, Schrag D, Somerfield MR, et al. American Society of Clinical Oncology recommendations on adjuvant chemotherapy for stage II colon cancer. J Clin Oncol. 2004;22:3408-3419.
11. Bosset J, Calais G, Mineur L, et al. Preoperative radiation (Preop RT) in rectal cancer: effect and timing of additional chemotherapy (CT) 5-year results of the EORTC 22921 trial. J Clin Oncol. 2005;23:247s.
12. Cunningham D, Humblet Y, Siena S, et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med. 2004;351:337-345.
13. Andre T, Boni C, Mounedji-Boudiaf L, et al. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med. 2004;350:2343-2351.
14. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med. 2004;350:2335-2342.
15. Marijnen CA, Nagtegaal ID, Kapiteijn E, et al. Radiotherapy does not compensate for positive resection margins in rectal cancer patients: report of a multicenter randomized trial. Int J Radiat Oncol Biol Phys. 2003;55:1311-1320.
16. Wibe A, Rendedal PR, Svensson E, et al. Prognostic significance of the circumferential resection margin following total mesorectal excision for rectal cancer. Br J Surg. 2002;89:327-334.
17. Baxter NN, Morris AM, Rothenberger DA, et al. Impact of preoperative radiation for rectal cancer on subsequent lymph node evaluation: a population-based analysis. Int J Radiat Oncol Biol Phys. 2005;61:426-431.
18. Janjan NA, Abbruzzese J, Pazdur R, et al. Prognostic implications of response to preoperative infusional chemoradiation in locally advanced rectal cancer. Radiother Oncol. 1999;51:153-160.
19. Janjan NA, Crane C, Feig BW, et al. Improved overall survival among responders to preoperative chemoradiation for locally advanced rectal cancer. Am J Clin Oncol. 2001;24:107-112.